JAMDA
Volume 8, Issue 4 , Pages 248-252 , May 2007

Do Herbal Agents Have a Place in the Treatment of Sleep Problems in Long-Term Care?

  • Mark Shimazaki, DO

      Affiliations

    • University of California, Los Angeles, Multicampus Program in Geriatric Medicine and Gerontology, Los Angeles, CA
    • ,
  • Jennifer L. Martin, PhD

      Affiliations

    • University of California, Los Angeles, Multicampus Program in Geriatric Medicine and Gerontology, Los Angeles, CA
    • VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center, Sepulveda, CA.
    • Corresponding Author InformationAddress correspondence to Jennifer L. Martin, PhD, VA Sepulveda GRECC (11E), 16111 Plummer Street, North Hills, CA 91343.

References 

  1. Lichstein KL, Durrence HH, Riedel BW, Taylor DJ, Bush AJ. Epidemiology of sleep. Mahwah, NJ: Lawrence Erlbaum Associates; 2004;
  2. Bliwise DL. Review: Sleep in normal aging and dementia. Sleep. 1993;16:40–81
  3. Bliwise DL. Normal aging. In:  Kryger MH,  Roth T,  Dement WC editor. Principles and Practice of Sleep Medicine. Philadelphia: W.B. Saunders Company; 1994;
  4. Bliwise DL. Normal aging. In:  Kryger MH,  Roth T,  Dement WC editor. Principles and Practice of Sleep Medicine. 4th ed.. Philadelphia: Elsevier Saunders; 2004;p. 24–38
  5. Martin JL, Webber AP, Alam T, et al. Daytime sleeping, sleep disturbance and circadian rhythms in nursing home residents. Am J Geriatr Psychiatry. 2006;14:121–129
  6. Voyer P, Verreault R, Mengue PN, et al. Prevalence of insomnia and its associated factors in elderly long-term care residents. Arch Gerontol Geriatr. 2006;42:1–20
  7. National Sleep Foundation. 2003 “Sleep in America” poll. Available at: www.sleepfoundation.org/polls/2003SleepPollExecutiveSumm.pdf. Accessed August 12, 2005.
  8. Grzywacz JG, Lang W, Suerken C, et al. Age, race and ethnicity in the use of complementary and alternative medicine for health self-management. J Aging Health. 2005;17:547–572
  9. Ness J, Cirillo DJ, Weir DR, et al. Use of complementary medicine in older Americans: Results from the health and retirement study. Gerontologist. 2005;45:516–524
  10. Valerian: product review. Available at: www.consumerlab.com. Accessed August 12, 2005.
  11. Avidan AY, Fries BE, James ML, et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc. 2005;53:955–962
  12. Ray WA, Thapa PB, Gideon P. Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc. 2000;48:682–685
  13. Granek E, Baker SP, Abbey H, et al. Medications and diagnoses in relation to falls in a long-term care facility. J Am Geriatr Soc. 1987;35:503–511
  14. Schneeweiss S, Wang PS. Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information. J Am Geriatr Soc. 2005;53:948–954
  15. National Center for Complimentary and Alternative Medicine. The use of complementary and alternative medicine in the United States. Washington DC: National Institutes of Health; 2004;Ref Type: Generic
  16. Santos MS, Ferreira F, Cunha AP, et al. Synaptosomal GABA release as influenced by valerian root extract—involvement of the GABA carrier. Arch Int Pharmacodyn Ther. 1994;327:220–231
  17. Dietz BM, Mahady GB, Pauli GF, et al. Valerian extract and valerenic acid are partial agonists of the 5-HT[5a] receptor in vitro. Brain Res Mol Brain Res. 2005;138:191–197
  18. Schumacher B, Scholle S, Holzl J, et al. Lignans isolated from valerian: Identification and characterization of a new olivil derivative with partial agonistic activity at A[1] adenosine receptors. J Nat Prod. 2002;65:1479–1485
  19. Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: A pilot study. Pharmacopsychiatry. 1995;27:147–151
  20. Vorbach EU, Gortelmeyer R, Bruning J. Therapie von insomnien: wirksamkeit und vertraglichkeit eines baldranpraparats (Therapy for insomniacs: effectiveness and tolerance of valerian preparations), Psychopharmakotherapie. 1996;3:109–115
  21. Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001;86:4727–4730
  22. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease. Sleep. 2003;26:893–901
  23. Kamm-Kohl AV, Jansen W, Brockmann P. Moderne baldriantherapie gegen vervose storungen im semium (Modern valerian therapy for nervous disorders in old age), Med Welt. 1984;35:1450–1454
  24. Valerian officinalis. (monograph) Alternative Medicine Reviews. 2004;9:438–441
  25. Stevinson C, Ernst E. Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Med. 2000;1:91–99
  26. Dorn M. [Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study]. Forsch Komplementarmet Klass Naturheikd. 2000;7:79–84German
  27. Ziegler G, Ploch M, Miettenen-Baumann A, et al. Efficacy and tolerability of valerian extract LI 156 compared with oxazepam in the treatment of non-organic insomnia—a randomized, double-blind, comparative clinical study. Eur J Med Res. 2002;7:480–486
  28. Donath F, Quispe S, Diefenbach K, et al. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000;33:47–53
  29. Poyares DR, Guilleminault C, Ohayon MM, et al. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal?. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:539–545
  30. Medline plus. Drugs, supplements, and herbal Information. Available at: www.nlm.nih.gov/medlineplus/druginformation.html. Accessed October 7, 2006.
  31. Arendt J. Chronobiology of melatonin. ISI Atlas Sci-Pharmacol. 1987;1:257
  32. Almeida Montes LG, Ontiveros Uribe MP, Cortes Sotres J, et al. Treatment of primary insomnia with melatonin: A double-blind, placebo-controlled, crossover study. J Psychiatr Neurosci. 2002;28:191–196
  33. Olde Rikkert MG, Rigaud AS. Melatonin in elderly patients with insomnia (A systematic review). Z Gerontol Geriatr. 2001;34:491–497
  34. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50
  35. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. J Sleep Res. 2004;9:11–24
  36. Pires ML, Benedito-Silva AA, Pinto L, et al. Acute effects of low doses of melatonin on the sleep of young healthy subjects. J Pineal Res. 2001;31:326–332
  37. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48:301–310
  38. Zemlan FP, Mulchahey J, Scharf MB, et al. The efficacy and safety of the melatonin agonist [beta]-methyl-6-chloromelatonin in primary insomnia: A randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry. 2005;66:384–390
  39. Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7:312–318
  40. Natural medicines comprehensive database. Available at: www.naturaldatabase.com. Accessed October 18, 2006.

 Supported by a UCLA Claude Pepper Older Americans Independence Center (OAIC) (AG-10415; PI: Reuben) Career Development Award (PI: Martin) and the VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center, Sepulveda, CA.

PII: S1525-8610(06)00583-4

doi: 10.1016/j.jamda.2006.11.001

JAMDA
Volume 8, Issue 4 , Pages 248-252 , May 2007

Article Tools